We are very proud to have received our first clinical trial application (CTA) approval in France, the Netherlands and the UK. We can now begin our planned phase I/IIa study of PN‑1007 for the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system, later in 2020. Read more: Press Release


In other news